A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Boston hospital only center in New England designated to treat Ebola patientson January 22, 2020 at 2:46 pm
As travel increases around the world, so does the risk of bringing contagious diseases home. In New England, Massachusetts General Hospital is the only designated treatment center for the Ebola virus.
- Winning community trust in Ebola controlon January 22, 2020 at 6:34 am
Butembo, (DRC), 22 January 2019 - “Why is Ebola taking so long to end?” a fierce-looking man in a community meeting outside Butembo town in the northeast of the Democratic Republic of the Congo (DRC) ...
- China coronavirus could have started out in bats linked to Ebola and SARSon January 22, 2020 at 5:47 am
China coronavirus may have roots in the same animal - the fruit bat - as Sars and Ebola, scientists studying the disease at the Centre for Disease Control and Prevention have said ...
- Sierra Leone's economy is still suffering after Ebola, but Idris Elba plans to help re-brand the nation and boost tourismon January 20, 2020 at 7:09 am
It has been almost four years since Sierra Leone was declared Ebola-free. Just as the West African country was getting back on its feet after more than a decade of civil war, the virus struck, killing ...
- The terror of catching Ebola inside a government superbug labon January 18, 2020 at 9:52 am
In February 2004, Kelly Warfield, a 28-year-old research scientist at the Fort Detrick Army base in Maryland, was investigating potential cures for Ebola. Working in a Biosafety Level 4 lab — the ...
- Despite outbreak, Ebola treatment and vaccine represent ‘resounding scientific success’on January 16, 2020 at 2:30 pm
Recently, the FDA formally approved the first vaccine to prevent the Ebola virus. The advance comes at a crucial time, as Democratic Republic of Congo is suffering an outbreak that has lasted over a ...
- The public science behind the ‘Merck’ Ebola vaccineon January 16, 2020 at 9:20 am
The U.S. Food and Drug Administration recently approved an important vaccine against Ebola, five years after an epidemic in West Africa killed 11,310 people and after more than 2,200 have died of it ...
- Mistrust Provokes Attack on Red Cross Volunteers in Ebola-Affected Community in DR Congoon January 16, 2020 at 8:20 am
The attack took place during a burial service for an Ebola victim in Ituri province. Two of the 18 Red Cross volunteers performing a burial service of a suspected Ebola victim Monday were seriously ...
- Why an Ebola Vaccine Is Not Enoughon January 16, 2020 at 2:10 am
But while it will save lives, it should not be viewed as a magic bullet for preventing and addressing future Ebola outbreaks. Above all, international donors must work closely with African governments ...
- Ebola outbreak in Democratic Republic of Congo: January crisis updateon January 15, 2020 at 9:19 pm
The current Ebola outbreak in Democratic Republic of Congo (DRC) is the worst on record in the country and the second-largest epidemic of the disease recorded anywhere. Almost a year-and-a-half after ...
via Bing News